Navigation Links
U.S. Physician Prescribing Behavior Impacted by Health Insurance Exchanges and Accountable Care Organizations
Date:10/24/2013

BURLINGTON, Mass., Oct. 24, 2013 /PRNewswire/ -- Decision Resources Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that pharmaceutical companies are facing a paradigm shift in the way their brands gain access to the U.S. market, as Accountable Care Organizations (ACOs) continue to develop across the nation and enrollment on the health insurance exchanges moves forward.

"Through our comprehensive surveys of physicians and MCO executives, we're able to see how the enormous changes in the U.S. healthcare market are affecting pharmaceutical brands.  When we looked at currently available and emerging brands by therapy, it was clear that some will benefit and others will be challenged," said Roy Moore, Senior Director at Decision Resources, a Decision Resources Group company. "For instance, looking at schizophrenia and depression, physician and payer responses suggest constrained use of branded therapies on exchange-based plans because of generic competition—even though they feel Abilify and Cymbalta will remain popular therapies. In light of the new dynamics shaping reimbursement decisions, pharmaceutical brand teams looking forward to 2014 vs. backward to 2013 will be crafting market access strategies that take changes like these into account."

ACOs, of which there are more than 500 across the US, will also impact prescribing behavior and brand uptake across therapies. For example, half of surveyed pulmonologists who participate in an ACO reduced their prescribing of the branded leukotriene inhibitor Singulair—while one-third assigned more of their patients to montelukast, a generic form of the same drug favored by ACO policies such as co-pay reductions. Similarly, 43% report they are less likely to prescribe Dulera because of their participation in an ACO whereas only 13% report increased prescribing of this agent. Yet the findings show that ACOs did not universally push physicians to generics—pulmonologists are evenly split in whether they increased or decreased prescribing of Advair (a competing combination therapy), highlighting how a brand can withstand the challenges stemming from new reimbursement models.

About Physician & Payer Forum Reports—2013 "Physician & Payer Dynamics" SeriesU.S. Physician & Payer Forum is the industry's only syndicated primary market research product that includes insights from both physicians and HMO/PPO pharmacy directors to get a true sense of how both parties shape a market. The 2013 "Physician & Payer Dynamics" Series investigates how novel payer-led care coordination and financing programs impact prescribing behavior.  The Series helps pharmaceutical brand managers and marketers develop effective market access strategies within the new paradigms brought about by Healthcare Reform. Find out more here.

2013 "Physician & Payer Dynamics" Report Titles:

  • NEW Healthcare Reform: Impact of Expanding Role for Medicaid and Health Exchanges on Prescribing of Schizophrenia, Bipolar Disorder and Unipolar Depression Drugs
  • NEW Payer Strategies and Access: Narrow Networks, Employed Physicians and Provider Consolidation's Impact on Prescribing Decisions for Cardiologists – Acute Coronary Syndrome and Post-Hospital Atrial Fibrillation
  • NEW Impact of Payer-Imposed Strategies on Market Access in NSCLC and Prostate Cancer: Clinical Pathways, Bundled Payments and Accountable Care Organization Contracting
  • NEW Market Access for High-Cost Brands in Multiple Sclerosis, Oncology, and Rheumatoid Arthritis
  • NEW Accountable Care Organizations: How Will Payer and Provider Adoption of this Model Impact Prescribing Trends in Asthma and COPD?
  • E-Prescribing and Electronic Health Records: Impact of Technology on Prescribing for Hypertension and Diabetes
  • About Decision Resources Group
    Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

    All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:  Lydia Smith

    Elizabeth MarshallDecision Resources Group

    Decision Resources Group 781-993-2594

    781-993-2563 lsmith@dresources.com

    emarshall@dresources.com  


    '/>"/>
    SOURCE Decision Resources Group
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Physician-Patient Alliance for Health & Safety: Maternal Morbidity on the Rise and Likely to Climb Even Higher
    2. KemPharm Forms Physician Advisory Council Advocating "Intelligent Pain Therapeutic Development"
    3. Dr. Michael Feiz on What Makes a Great Bariatric Physician
    4. Market Disruption Imminent as Hospitals and Physicians Aggressively Adopt Patient Portal Technology
    5. CMTC announces Physician Collaboration Platform ("PCP") Upgrade: A cloud-based telehealth solution for improved collaboration, access and performance
    6. Lack of Formulary Access Tops List of Limitations Primary Care Physicians Face With e-Prescribing Systems, Says New Research Report from SciMedica Group MR&C
    7. inVentiv Health Clinical Launches Physician Network For Late-Stage Research
    8. Unique Glaucoma Test Through Eyelid DIATON Opens Doctors Eyes to Possibility of In-Office Glaucoma Test at Pri-Med East and American Academy of Family Physicians, AAFP
    9. Update: 2013 List of Best Doctors in Dallas Features Texas Institute for Surgery Physicians
    10. 2013 List of Best Doctors in Dallas Features Texas Institute for Surgery Physicians
    11. Childhood Obesity Need Not Last a Lifetime, says Beverly Hills Physicians
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
    (Date:2/27/2017)... 27, 2017 A recent research report published ... market alone is expected to reach a value of $55.8 billion ... along with 28 states have legalized marijuana for medical uses. In ... Florida , North Dakota , ... to use the drug in medical applications such as chemotherapies and ...
    (Date:2/27/2017)... N.J. and PETACH TIKVAH, Israel ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... appointments of June S. Almenoff , M.D., Ph.D., ... to its Board of Directors.  "Dr. ... executives whose appointments come at an exciting time for ...
    Breaking Medicine Technology:
    (Date:2/27/2017)... , ... February 27, 2017 , ... The threat of ... to work for a company involved in the underground testing of nuclear weapons. Years ... for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical ...
    (Date:2/27/2017)... ... 2017 , ... Orange County dentist, Dr. A. Rassouli, comments on ... when the bacteria in plaque infect the gums and other tissues supporting the teeth. ... planing or SRP, and can include surgical therapies if the condition has led to ...
    (Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media ... system brings songs, movies, TV shows and much more apps for user exploration. Its ... An immersive view of 1280 x 720 provides crisp images with remarkable clarity and ...
    (Date:2/27/2017)... , ... February 27, 2017 , ... ... threshold mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count ... in March 2014. The company had 800 customers and 2,250 RCEs at the ...
    (Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... for hair transplantation therapy, is proud to announce a new informational post on ... therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) ...
    Breaking Medicine News(10 mins):